Sweden · Delayed Price · Currency is SEK Sprint Bioscience AB Company Description
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden.
The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer.
It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash.
It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases.
The company was incorporated in 2009 and is based in Huddinge, Sweden.
| Country | Sweden |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Johan Emilsson |
Contact Details
Address: Novum Huddinge, Stockholm County 141 57 Sweden | |
| Phone | 46 84 11 44 55 |
| Website | sprintbioscience.com |
Stock Details
| Ticker Symbol | SPRINT |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0006343745 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Johan Emilsson | Chief Executive Officer |
| Prof. Pär Nordlund | Founder |
| Dr. Martin Andersson | Co-Founder, Research Director and Chief Scientific Officer |
| Dr. Kenth Hallberg | Founder and Director of Structural Chemistry |
| Anne-Marie Wenthzel | Chief Business Officer |